Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

3.4%

1 terminated/withdrawn out of 29 trials

Success Rate

95.7%

+9.2% vs industry average

Late-Stage Pipeline

21%

6 trials in Phase 3/4

Results Transparency

14%

3 of 22 completed trials have results

Key Signals

2 recruiting3 with results

Enrollment Performance

Analytics

Phase 2

12(41.4%)

Phase 1

6(20.7%)

N/A

5(17.2%)

Phase 3

5(17.2%)

Phase 4

1(3.4%)

29Total

Phase 2(12)

Phase 1(6)

N/A(5)

Phase 3(5)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (29)

Showing 20 of 29 trials

NCT04532931Phase 2Completed

Four Different Experimental Drug Regimens to Standard of Care for the Treatment of Symptomatic Outpatients With COVID-19

Role: lead

NCT07064525Phase 2Enrolling By Invitation

Evaluate the Efficacy and Safety of SPC1001 Low in Patients With Essential Hypertension

Role: lead

NCT06660719Phase 3Recruiting

Efficacy and Safety of SP-8203 (Otaplimastat) in Patients With Acute Ischemic Stroke Receiving Thrombolytic Standard of Care

Role: lead

NCT06826872Phase 2Recruiting

Efficacy and Safety of SPC1001 in Patients With Essential Hypertension

Role: lead

NCT06399042Phase 3Active Not Recruiting

Pivotal Study to Evaluate Efficacy and Safety of SP5M002 Inj. as Compared to Synovian Inj. in Patients With Mild to Moderate Knee Osteoarthritis

Role: lead

NCT06307847Phase 3Completed

Pivotal Study to Evaluate Efficacy and Safety of SP5M001 Inj. as Compared to Synovian Inj. in Patients With Mild to Moderate Knee Osteoarthritis

Role: lead

NCT06225635Phase 1Completed

A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Ezerosu Tab

Role: lead

NCT06212648Phase 2Completed

Evaluate the Efficacy and Safety of SPC1001 and Monotherapy in Patients With Essential Hypertension

Role: lead

NCT01868438Phase 1Completed

Relative Bioavailability of Pyronaridine-artesunate in Tablet and Granule Formulations in Healthy Volunteers

Role: collaborator

NCT05084911Phase 3Completed

The Efficacy and Safety of Pyramax in Mild to Moderate COVID-19 Patients (Phase3)

Role: lead

NCT04479449Phase 2Completed

Efficacy and Safety of SP-8203 in Patients With Ischemic Stroke Requiring rtPA

Role: lead

NCT05633420Phase 2Completed

Pilot Clinical Trial to Explore Efficacy and Safety of Pyramax in Mild to Moderate COVID-19 Patients

Role: lead

NCT05574166Phase 1Terminated

A Phase I Study to Evaluate Safety and Pharmacokinetics of Escalating Single Doses and Multiple Doses of SP-8356

Role: lead

NCT01594931Phase 2Completed

Phase II Dose-ranging Study of Pyronaridine/Artesunate in Adults Patients With Plasmodium Falciparum Malaria

Role: collaborator

NCT04701606Phase 2Unknown

The Safety and Efficacy of Pyronaridine-artesunate (Pyramax® or Artecom®)in COVID-19 Patients

Role: lead

NCT04688281Not ApplicableCompleted

Spine Surgery for Adhesions in Patients Evaluated for Efficacy and Safety of MedicurtainⓇ (Pivotal Study)

Role: lead

NCT04672421Not ApplicableCompleted

The Efficacy and Safety of Medicurtain® in Patients With Total Laparoscopic Hysterectomy (Pivotal Study)

Role: lead

NCT04638855Not ApplicableCompleted

The Efficacy and Safety of Medicurtain® in Patients With Hysteroscopy (Pivotal Study)

Role: lead

NCT05058027Not ApplicableCompleted

Anti-adhesive Effect and Safety of MEDICURTAIN Applied to Undergoing Thyroid Surgery (Pivotal Study)

Role: lead

NCT05049434Not ApplicableCompleted

Efficacy and Safety for Medicurtain® in Prevention of Adhesion After Endoscopic Sinus Surgery (Pivotal Study)

Role: lead